hypocellular central areas of the chronic inactive lesions, thus being able to confirm that axonal loss correlates with the degree of inflammation in the disease, being present as from early stages of the disease 2 . Although the molecular mechanisms involved in the process of axonal damage are not exactly known, several hypothesis have been proposed 7 . It is known that myelin loss produces a failure in axonal action potential conduction, and this is sometimes seen from the clinical standpoint as neurologic deficit 8 . However, this axonal conduction can be recovered due to the expression and distribution of new sodium channels in the demyelinated axon, resulting in total or partial deficit remission 8 . This voltage -dependent sodium channels might probably play an important role in the neurodegenerative process seen in MS 9 . A consequence of axonal loss in a lesion is Wallerian degeneration along the fiber pathways that traverse it 2 . Axonal loss in lesions may therefore cause atrophy by two mechanisms: tissue loss within the lesion per se, and Wallerian degeneration in related fiber pathways. Given the large proportion that axons contribute to white matter volume, and evidence for considerable axonal damage in MS, axonal loss seems likely to be an important contributor to the atrophy observed in the disease 2, 10, 11 .
technical considerations in Brain atrophy MeasureMent in Ms
Currently, global and regional brain atrophy can be assessed using a wide variety of techniques 4, 12, 13, 14 . Some of these utilize manual methods for the quantitative analysis of the atrophy (such as bidimensional measurement of lateral ventricle diameter or of the third ventricle diameter, among others). Nevertheless, in spite of being simple and user friendly for an experienced operator, these methods carry important disadvantages because they not only require a prolonged analysis time but also demonstrate significant inter-observer variability 14 . As an alternative for this reproducibility hurdle, the automated segmentation techniques do not require interaction with the operator, they can process a larger number of images, and they eliminate the variability. The automation process of volumetric measurements has been possible because both MRI images (tridimensional sequences) and their processing through specific programs have improved 4 . These programs have allowed us to obtain more precise and reproducible measurements of brain atrophy in patients with MS. Automated or semi-automated measurement techniques can be divided in two groups: segmentation techniques (transversal) and registry techniques (longitudinal) 4 .
segMentation Based techniques (transversal)
Segmentation based techniques (transversal) allow us to perform total brain volume measurements, either of white or gray matter, globally or regionally, in a certain time period 4, 14 . One of the most commonly used techniques estimates brain parenchymal fraction (BPF), which is defined as the relationship between brain parenchyma volume and intra-cranial volume (obtained by the sum of the brain parenchyma and the cerebrospinal fluid (CSF)), or brain parenchyma/brain parenchyma + CSF
15
. The advantage of this technique is that both the brain parenchyma and the intra-cranial volume are measured in an automated fashion and skull size variability is considered for each patient separately.
registry Based techniques (longitudinal)
These registry based techniques allow us to perform longitudinal measurements of changes in brain atrophy 4, 14 . The comparison of serial evaluations performed in a patient, or in a group of patients, quantifies changes that have occurred in brain volume during a certain time-frame. These techniques, which are largely automated, express results as a percentage of change in brain volume 4 . In Table 1 commonly techniques used for the measurement of brain atrophy can be seen, together with their main limitations and characteristics.
Brain atrophy and the existing evidence concerning its Meaning

Brain atrophy and the risk of disease progression
We have thoroughly evaluated the role of brain atrophy as a prognostic factor in the progression of the disease. As previously mentioned, brain atrophy is detected in the early stages of the disease, even in stages without clinical symptoms 16, 17 . It has already been demonstrated that the rate of brain atrophy is greater in patients with a clinically isolated syndrome (CIS) that progresses to MS when compared with patients that do not worsen during the course of their disease. This impacts the early prognosis of the disease
18
. A sub-analysis from the ETOMS study that assessed the efficacy of [sc] interferon beta 1-a sc in patients with CIS showed a significant difference in mean annual percentage brain volume change (PBVC) between patients who had disease progression and those who did not (-0.92% and -0.56%, respectively) 19 . Similar findings were identified in an observational study done by Pérez-Miralles et al. 5 which showed a greater decrease of PBVC in 176 patients with CIS who progressed to MS when compared to those patients who did not progress (-0.65% compared to +0.059%, p < 0.001). These findings established a prognostic role for brain atrophy and MS conversion in patients who had a first demyelinating event. Di Filippo et al. 18 also demonstrated the prognostic role of brain atrophy and the risk of progression to MS after a first clinical event. In their studies, those patients with CIS that progressed to MS during a 6 year follow-up had an atrophy rate of 0.5% vs. -0.2% of those who did not, thereby making this an important prognostic factor for MS conversion 18 ( Figures 1 and 2 ).
clinical iMpact of Brain atrophy in patients with Ms
A study from Fisher et al. 20 published in 2002 showed the relationship between brain atrophy and physical impairment during an 8-year follow-up. This study also stated that brain atrophy had a clinical impact: worsening expanded disability status scale (EDSS) and progression to disability. A correlation between atrophy rate and physical disability was performed and suggesting that progression to atrophy in relapsing remitting multiple sclerosis (RRMS) was clinically relevant and may be a useful marker to predict disease progression 20 . Following this line of research, Fisniku et al. 21 evaluated whether physical disability during follow-up was related to white and gray matter brain atrophy. The study included 73 patients with CIS who were followed up for almost 20 years showed that atrophy of gray matter was related to an increase in EDSS (p < 0.001) and a worsening in the functional assessment of the patients (p < 0.001) in a higher proportion than in the atrophy of the white matter 21 . Sailer et al. 22 identified that a greater thinning of the global cortical thickness, and specially the motor cortex, related to worse performance in physical assessment and an increase in EDSS (p = 0.001) during follow-up in patients with MS. These studies support the finding that more significant brain atrophy correlates with a worsening of physical Box plots that show in another study the risk of multiple sclerosis (MS) conversion during follow-up in patients with CIS. Higher atrophy during the first year of disease implies a greater risk 18 .
disability in patients with MS. The remainder of the evidence concerning this issue is explained in detail in Table 2 .
Brain atrophy and cognitive iMpact in Ms patients
The impact of brain atrophy in the cognitive field can be seen as from the pre-morbid stage of the disease, known as the radiologic isolated syndrome (RIS) 16 . Amato et al. reported that 27.6% of these patients had signs of cognitive deterioration and that cortical brain volume reduction related to a worse performance in cognitive tests (p = 0.043) 35 . In patients with RRMS, the finding of regional atrophy has been related to specific functional involvement. For example, atrophy of the corpus callosum (CC) has been related to a worsening in verbal fluency tests as well as in attention tests, as measured by the Symbol Digit Modality Test (SDMT) and the PASAT test. Atrophy of the anterior segment of the CC has been related to fatigue and its degree of severity 36 . Likewise, Rudick et al. 37 showed a correlation between gray matter atrophy progression and worsening of the MSFC. Table 3 shows the evidence that impact atrophy has on the cognitive field. 
iMpact of disease Modifying therapies on Brain atrophy
Based upon these findings, there is a clear need to identify medication not only for the inflammatory process but also for preventing brain atrophy progression and neurodegeneration. Currently, the effect of medication on MS and its secondary impact on brain atrophy is under investigation. However, in some phase III clinical trials the brain atrophy biomarker has become a primary assessment outcome.
In a study that included 519 patients with RRMS for a two-year period, the subcutaneous administration of interferon b-1a 53 , found no effect of treatment on brain atrophy when compared to placebo. In another study that used glatiramer acetate in the evaluation, there were no differences in brain atrophy during follow-up in the placebo arm 54 . In studies that used teriflunomoide no significant changes in brain atrophy were found when compared to the placebo arm, whereas in those studies that assessed fingolimod and BG-12 (FREEDOMS and TRANSFORMS and DEFINE studies) showed significant differences in atrophy rate reduction when compared with no treatment or active drug 55, 56, 57, 58, 59 . In a recent meta-analysis conducted by Sormani et al. 60 , the researchers were able to demonstrate the impact of controlling degenerative activity with the current available MS treatments. This degenerative activity was reflected in the atrophy (Table 4 ). The main findings of the overall analysis showed that a greater reduction in brain atrophy led to reduced disability progression in the two-year follow-up period assessed 60 . Brain atrophy might also have a greater predictive value than conventional MRI findings in preventing physical disability progression (lesional load in T2).
conclusion
In this review we describe the current available evidence regarding brain atrophy and its consequence in MS patients. MS has traditionally been considered a white matter inflammatory disease. Today, there is a large body of evidence that supports the hypothesis that gray matter involvement and the neurodegenerative mechanisms are at least partially independent from inflammation in this disease.
The neurodegenerative mechanism creates permanent damage and correlates with physical and cognitive disability. Therefore, it is important to treat MS in the early stages to decrease the loss of brain volume and its consequences. Some issues should be overcome in order to increase it´s use and confidence, like the influence that brain water content could have on the measurement as well as the cut off value of annual brain atrophy that should be used in daily clinical practice for example. Regarding the first issue, many research lines addressed the issue and showed that the inclusion of pseudo T2 sequences as well as frequent MR scans can serve as a marker of changes in bulk brain water content and thus can help to investigate the presence of pseudoatrophy in multiple sclerosis vs. real brain volume loss in order to better characterize the temporal pattern of brain volume change in affected patients. The other issue mentioned is the cut off value in annual brain volume loss. De Stefano et al. demonstrates that different values of annual PBVC could define a pathological range at different levels of specificity (ie, 'pathological' rates could be defined as above -0.52% with a specificity of 95%, above -0.46% with a specificity of 90% and above -0.40% with a specificity of 80%) and interestingly, increasing age did not influence in such references cut-off values. Establishing cut-offs will allow to discriminate between physiological and pathological rates in patients with MS, however is currently a difficult task in MS. Despite the relevance that brain volumetric has demonstrated, it´s use has not yet being translated into clinical practice. However, advances in computational technology are paving the way for a more disseminated use in MS as well as other neurological disorders.
